IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

ZAGAMI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.033
AS - Asia 2.757
NA - Nord America 2.029
SA - Sud America 281
AF - Africa 67
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.188
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.932
DE - Germania 1.580
SG - Singapore 823
CN - Cina 765
IT - Italia 497
HK - Hong Kong 360
VN - Vietnam 266
SE - Svezia 234
BR - Brasile 205
RU - Federazione Russa 162
IN - India 149
BD - Bangladesh 139
GB - Regno Unito 116
FR - Francia 110
NL - Olanda 96
FI - Finlandia 84
CA - Canada 45
JP - Giappone 41
IE - Irlanda 37
KR - Corea 34
CI - Costa d'Avorio 29
ID - Indonesia 29
TR - Turchia 29
AR - Argentina 28
PH - Filippine 23
MX - Messico 19
AT - Austria 18
ES - Italia 18
AU - Australia 15
PL - Polonia 13
SA - Arabia Saudita 13
EC - Ecuador 12
IQ - Iraq 12
UZ - Uzbekistan 12
ZA - Sudafrica 12
JM - Giamaica 11
PK - Pakistan 10
UA - Ucraina 10
CL - Cile 9
CO - Colombia 9
KE - Kenya 8
TT - Trinidad e Tobago 8
VE - Venezuela 8
BE - Belgio 7
CH - Svizzera 7
CZ - Repubblica Ceca 7
AM - Armenia 6
EG - Egitto 6
IR - Iran 6
PE - Perù 6
RO - Romania 6
TW - Taiwan 6
NO - Norvegia 5
PS - Palestinian Territory 5
CR - Costa Rica 4
JO - Giordania 4
MA - Marocco 4
MY - Malesia 4
NZ - Nuova Zelanda 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
DZ - Algeria 3
IL - Israele 3
KZ - Kazakistan 3
LT - Lituania 3
SV - El Salvador 3
TH - Thailandia 3
BY - Bielorussia 2
GE - Georgia 2
GT - Guatemala 2
LV - Lettonia 2
MO - Macao, regione amministrativa speciale della Cina 2
PA - Panama 2
PY - Paraguay 2
RS - Serbia 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GI - Gibilterra 1
GR - Grecia 1
GU - Guam 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
NI - Nicaragua 1
OM - Oman 1
PT - Portogallo 1
Totale 8.184
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 1.468
Singapore 382
Ashburn 367
Hong Kong 309
Dallas 271
San Jose 192
Hefei 175
Milan 145
Los Angeles 98
Beijing 89
Chandler 87
Council Bluffs 79
Santa Clara 76
Ho Chi Minh City 75
Hanoi 73
New York 62
Bengaluru 56
Southend 52
Helsinki 51
Lauterbourg 47
Boardman 39
Moscow 38
Dublin 37
Buffalo 34
Munich 34
Shanghai 34
Tokyo 33
Abidjan 29
Guangzhou 29
Seoul 27
Rome 25
Princeton 24
Istanbul 22
Düsseldorf 21
Jakarta 21
Hyderabad 20
Lappeenranta 19
Naples 17
São Paulo 17
Toronto 16
Chennai 15
Da Nang 15
Cangzhou 14
Orem 13
Atlanta 12
Chicago 12
Des Moines 12
Turku 12
Berlin 11
Boston 11
Changsha 11
Fuzhou 11
Haiphong 11
Nuremberg 11
Paris 11
Turin 11
Vienna 11
Amsterdam 10
Bari 10
Florence 10
London 10
Phoenix 10
Seattle 10
Tashkent 10
Kingston 9
Mexico City 9
Mumbai 9
Salt Lake City 9
Cambridge 8
Denver 8
Fairfield 8
Rio de Janeiro 8
Shenzhen 8
Tianjin 8
Bologna 7
Brooklyn 7
Brussels 7
Columbus 7
Houston 7
Oklahoma City 7
The Dalles 7
Warsaw 7
Washington 7
Wuhan 7
Baghdad 6
Bexley 6
Buenos Aires 6
Genoa 6
Guayaquil 6
Hải Dương 6
Nairobi 6
Nanjing 6
Sydney 6
Thái Bình 6
Biên Hòa 5
Brasília 5
Brisbane 5
Bucharest 5
Dong Ket 5
Fisciano 5
Totale 5.208
Salva come PNG Salva come JPEG
Nome #
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure 317
Metaplastic breast cancer: an all-round multidisciplinary consensus 250
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 245
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 243
Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature 237
Systemic Treatment of Ductal Carcinoma In Situ of the Breast 237
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial 222
Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion 214
Evolution of low HER2 expression between early and advanced-stage breast cancer 214
Assessing predictors of tamoxifen nonadherence in patients with early breast cancer 209
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2 201
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer 201
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer 200
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 199
Triple negative breast cancer: Pitfalls and progress 193
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment 192
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers 191
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 190
What therapies are on the horizon for HER2 positive breast cancer? 190
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 185
First line treatment of BRAF mutated advanced melanoma: Does one size fit all? 181
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 177
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer 163
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 162
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? 161
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors 160
Characterization of low HER2 expressions in de-novo metastatic breast cancer 158
Cardiotoxicity of Agents Used in Patients With Breast Cancer 145
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents 144
Molecular tumor board in patients with metastatic breast cancer 142
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations 141
Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist 140
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment 139
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology 135
Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer 135
Antibody-drug conjugates in breast cancer : the chemotherapy of the future? 132
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases 126
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 121
Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives 117
HER2-positive breast cancer: cotargeting to overcome treatment resistance 117
Management of Cardiac Toxicity Induced by Chemotherapy 113
Multimodal histopathologic models stratify hormone receptor-positive early breast cancer 107
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences 106
UNDERSTANDING METASTASIS MIXED - TREATMENT RESPONSES THROUGH GENOMIC ANALYSES. 96
Understanding metastasis mixed-treatment responses through genomic analyses 86
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative 86
Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing? 85
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC) 83
The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: A case series and literature review 83
Spectral CT for non-invasive evaluation of bladder cancer grade 76
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 75
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials 61
EGFR-TKI plus anti-angiogenic drugs in EGFR-mutated non–small cell lung cancer: A meta-analysis of randomized clinical trials 58
Different Response to Immunotherapy According to Melanoma Histologic Subtype 50
New Concepts in Cardio-Oncology 18
null 6
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer 6
Comprehensive Diagnostic and Therapeutic Approaches for Estrogen Receptor-Low Breast Cancer: A Multidisciplinary Perspective From Oncologists and Pathologists 5
null 3
Pembrolizumab and oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1) 3
null 3
Impact of breast cancer on sexuality and psycho-physical wellbeing: Survey analysis 1
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer 1
Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions 1
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Protocol for the development and testing of a web-based patient decision aid for early-stage breast cancer patients within a cancer centre care: a mixed-method approach 1
Proton therapy in breast cancer: bridging medical and radiation oncology 1
Molecular tumour board in gastrointestinal cancers 1
Corrigendum to: "Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis" [Eur J Cancer 145 (2021) 197-209] 1
Totale 8.443
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.693
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.693
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202143 0 0 0 0 0 0 0 0 0 0 21 22
2021/2022275 8 16 10 40 24 23 11 20 45 9 29 40
2022/2023325 53 45 35 18 22 51 3 20 38 5 23 12
2023/20241.380 21 34 40 49 103 74 197 162 78 173 227 222
2024/20252.082 191 187 170 160 101 71 51 164 114 193 218 462
2025/20264.287 488 496 588 395 292 159 603 215 352 261 438 0
Totale 8.443